Gefitinib CAS 184475-35-2 daahirnimo>99.5% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. waa saaraha ugu horreeya ee Gefitinib (CAS: 184475-35-2) oo leh tayo sare.Kiimikada Ruifu waxay bixin kartaa gaarsiinta adduunka oo dhan, qiimo tartan ah, adeeg aad u wanaagsan, tiro yar iyo tiro badan oo la heli karo.Iibso Gefitinib iyo dhexdhexaadiyeyaasha,Please contact: alvin@ruifuchem.com
| Magaca Kiimikada | Gefitinib |
| La mid ah | Saldhigga Xorta ah ee Gefitinib;Iressa;ZD1839;ZD-1839;N- (3-Chloro-4-Fluorophenyl) -7-Methoxy-6- (3-Morpholinopropoxy) quinazolin-4-Amine;N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-[3- (4-Morpholinyl) propoxy]-4-Quinazolinamine |
| Heerka Saamiyada | Suuqa dhexdiisa, Wax-soo-saarka Ganacsiga |
| Lambarka CAS | 184475-35-2 |
| Qaanuunka molecular | C22H24ClFN4O3 |
| Miisaanka Molecular | 446.91 g/mol |
| Meesha dhalaalaysa | 194.0 ilaa 198.0 ℃ |
| Cufnaanta | 1.322± 0.06 g/cm3 |
| Biyuhu milmayn | Aan ku milmin Biyaha |
| Solubility | Ku milmay DMSO |
| Heerkulka Kaydinta | Heerkulka qolka |
| Raridda | Ambient |
| COA & MSDS | La heli karo |
| Asal ahaan | Shanghai, Shiinaha |
| Summada | Kiimikada Ruifu |
| Walxaha | Heerarka Kormeerka | Natiijooyinka |
| Muuqashada | Caddaan ilaa budo cad-cad | U hogaansama |
| Khasaare xagga qalajinta | <0.50% | 0.13% |
| Hadhaaga dabka | <0.20% | 0.06% |
| Xumaanta Keliya | <0.10% | 0.09% |
| Wadarta wasakhda | <0.50% | 0.20% |
| Biraha culus (Pb) | ≤10pm | <10pm |
| Daahirnimada / Habka Falanqaynta | > 99.5% (HPLC) | 99.80% |
| Infrared Spectrum | Waafaqsan Qaab-dhismeedka | U hogaansama |
| 1H NMR Spectrum | Waafaqsan Qaab-dhismeedka | U hogaansama |
| Gabagabo | Alaabtu waa la tijaabiyay oo waafaqday tilmaamihii la bixiyay | |
Xidhmada:Dhalada fluorinated, bacda bireed aluminium, 25kg/Drum kartoonada, ama sida waafaqsan shuruudaha macmiilka.
Xaaladda Kaydinta:Weelka si adag u xidh oo ku kaydi bakhaar qabow, engegan oo hawo wanaagsan leh oo ka fog walxaha aan ku habboonayn.Ka ilaali iftiinka iyo qoyaanka.
Rarida:Ku gaarsii adduunka oo dhan hawo, by FedEx/DHL Express.Bixi keenid degdeg ah oo la isku halayn karo.
Looma isticmaalo dadka.Looma isticmaalo baadhista ama daaweynta.Si loo isticmaalo cilmi-baarista in vitro kaliya.
Midkoodna badeecadaha lama siin doono wadamada ay tani ka hor iman karto shatiyada jira.Si kastaba ha ahaatee mas'uuliyadda kama dambaysta ah waxay saaran tahay iibsadaha.
Sidee loo Iibsadaa?Fadlan la xidhiidhDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Khibrad 15 Sano ah?Waxaan leenahay in ka badan 15 sano oo waayo-aragnimo ah oo ku saabsan soo saarista iyo dhoofinta ee tiro balaadhan oo ah dhexdhexaad ah daawooyinka tayada sare leh ama kiimikooyinka ganaax.
Suuqyada Waaweyn?Iibiya suuqa gudaha, Waqooyiga Ameerika, Yurub, Hindiya, Kuuriya, Jabbaan, Australia, iwm.
Faa'iidooyinka?Tayada sare, qiimo jaban, adeegyo xirfadeed iyo taageero farsamo, gaarsiin degdeg ah.
TayadaHubinta?Nidaamka xakamaynta tayada adag.Qalabka xirfadlayaasha ah ee falanqaynta waxaa ka mid ah NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Imtixaanka xadka Microbial, iwm.
Tusaalooyinka?Badeecadaha intooda badani waxay bixiyaan muunado bilaash ah oo loogu talagalay qiimeynta tayada, kharashka dhoofinta waa in ay bixiyaan macaamiisha.
Hantidhawrka Warshada?Hantidhawrka warshada soo dhawoow.Fadlan horay u sii ballan.
MOQ?Ma jiro MOQ.Dalabka yar waa la aqbali karaa.
Waqtiga dirida? Haddii ay ku jirto kaydka, dammaanad bixinta saddex maalmood ah.
Gaadiidka?By Express (FedEx, DHL), hawada, badda.
Dukumentiyada?Adeegga iibka kadib: COA, MOA, ROS, MSDS, iwm waa la bixin karaa.
Isku-dhafka gaarka ah?Waxay ku siin kartaa adeegyada isku-dhafka gaarka ah si ay ugu habboonaato baahiyahaaga cilmi-baarista.
Shuruudaha Lacag-bixinta?Qaansheegga Proforma ayaa marka hore la soo diri doonaa ka dib marka la xaqiijiyo dalabka, oo lagu soo lifaaqay macluumaadka bangigayaga.Lacag bixinta T/T (Telex Transfer), PayPal, Western Union, iwm.
| Sharaxaada Badbaadada | 24/25 - Iska ilaali taabashada maqaarka iyo indhaha. |
| Koodhka HS | 2934999099 |
Gefitinib (CAS: 184475-35-2) waa daawo daaweyneed oo gaar ah oo gaar ah oo ka hortagta burada oo ay samaysay AstraZeneca, UK.Waa daawada ugu horraysa ee la bartilmaameedsado molecular ee daawaynta kansarka sambabada unugyada aan yarayn.Waxay u shaqeysaa iyada oo si xushmad leh u joojinaysa dariiqa wareejinta calaamadaha ee tayrosine kinase factor koritaanka epidermal (EGFR-TK).Qodobka koritaanka Epidermal (EGF) waa polypeptide leh cufnaanta molecular ee 6.45 × 103, kaas oo isku dari kara xuubka koritaanka epidermal (EGFR) ee xuubka unugyada bartilmaameedka si uu u soo saaro saameynta noolaha.EGFR waa tyrosine kinase (TK) nooca reseptor.Marka ay ku xiran tahay EGF, waxay kor u qaadi kartaa firfircoonida TK ee jirka qaataha, taasoo keentay autophosphorylation ee hadhaaga tyrosine, bixinta calaamadaha qaybinta joogtada ah ee unugyada, taasoo keenta kororka unugyada iyo kala duwanaanta.EGFR waxay ku badan tahay unugyada aadanaha waxaana aad loogu muujiyaa burooyinka halista ah.Iyada oo la xannibayo dariiqa calaamadaynta EGFR ee dusha unugyada, gefitinib wuxuu horjoogsadaa korriinka burada, metastasis iyo angiogenesis, wuxuuna keeni karaa apoptosis unugyada burooyinka.Bishii Agoosto 2002, gefitinib ayaa markii ugu horreysay lagu suuq geeyey Japan sida daawaynta safka koowaad ee kansarka sambabada unugyada yaryar ee hoos yimaada magaca ganacsiga Iressa.Bishii Maajo 2003, Maamulka Cuntada iyo Dawooyinka ee Mareykanka ayaa oggolaaday gefitinib inuu yahay monotherapy safka saddexaad ee bukaannada qaba kansarka sambabada unugyada aan yareyn ee horumarsan kuwaas oo aan waxtar u lahayn daawooyinka kansarka ee platinum-ku-saleysan iyo daaweynta kiimikaad docetaxel.Waqtigan xaadirka ah, waxa ay u ansixiyeen Australia, Japan, Argentina, Singapore iyo South Korea daawaynta kansarka sambabada unug yar oo horumarsan.Febraayo 28, 2005, Maamulka Cunnada iyo Dawooyinka ee Shiinaha ayaa oggolaaday gefitinib si loogu daaweeyo kansarka sambabada unugyada aan unugyada yaryar ee gudaha ama metastatic (NSCLC) oo hore u qaatay kiimoterabi.Hadda looma ogola in loo isticmaalo daawaynta safka kowaad ee NSCLC sare.Bishii Luulyo 1, 2009, Hay'adda Daawooyinka Yurub waxay si rasmi ah u ansixisay gefitinib ee safka koowaad, laynka labaad iyo daawaynta safka saddexaad ee kansarka sanbabada unug yar ee gudaha ama metastatic oo leh isbeddellada hidda-wadaha EGFR ee dadka waaweyn.
